Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I believe this was covered a while ago, but they are not in competition with each other. IIRC they are both targeting different stages of Covid.
Plenty if money to be made from being invested in both companies like myself and a few others in here.
Strictlyinc, ‘ Think it might just be SNG last one standing!’
Or maybe Tiziana will be the last one standing?
I’ve looked at SNG as it’s a company located near to where I live. I’ve preferred the TILS option though and I like the fact that if the Brazil Covid trials don’t produce there is still the fallback of Crohns and MS for Foralumab. Then there’s also Milciclib within the pipeline so plenty of cover and potential here.
Love your positivity- not !! Folk also need to remember that the Covid play was a late addition and a Brucy bonus if it comes off. !
Greend.. its funny I was just going to message you.. ive been hiding too mostly over the last week or two lol im planning on reading some of Dr Weiners work over the weekend. He has some interesting stuff on immune modulators/mAb im sure. Will let you know if I find something of note. Have a good weekend all
Is it safe to come back yet?? Bonkers week...understood none of it (lack of climb, fall on Friday etc...)...always best to stick to the fundamentals of the business rather than trying to understand the markets...
Good post SK...as usual...hoping for a more normal week next week...:-)
On the news flow, I would expect that to increase in the US now, been very quiet for a couple of months, and hoping for some positive news flow this week.
I know others have mentioned you can't hold back news flow but you can reasonably easily... Some things you have complete control over - like main market timings - others, like contract agreements you can hold off on contract signings to time in with macro factors, so still have some control on those things...hopefully a couple of updates due (other than its the 27th, no it's the 29th, it's the 30th...).
Have a good weekend folks...hoping normal service resumes next week!
Usain, ours is a completely different mechanism to these. If this worked our patent would not have even covered it. These trials basically make antibodies same as those produced by your body to fight the infection, they go back into the human and help lower the viral load. Our trial uses foralumab to lower hyper immune response to stop body damaging lungs (cytokine storm). These trials dont really affect us. Plus like you mention our delivery method is different also. With covid out of control, national lockdown soon perhaps... now would be a good time to start a covid trial with results before christmas
@Usain_ Regeneron trial was stopped due to risks, not ineffectiveness.
It is already known that introducing antibodies to the bloodstream can have a plethora of unexpected side effects, hence the clinical study, but based on their risk assessment they decided it's not worth it for "very sick patients", but they're still enrolling other types.
Another point I would like to add is the source of the antibodies, TILS' is the only fully human monoclonal antibody, which minimizes the risk of adverse effects when introduced to the body, combine that with being introduced directly to the infected organ (i.e. the lungs) and you greatly increase its effectiveness, at the same time greatly decreasing it's risk of spreading to other organs via bloodstream and causing any adverse effects.
For the above reasons, I'm very positive about our upcoming Covid trial, and looking forward to great results.
In the end, this is just my own interpretation, but I hope it answers your concerns.
@whimax
Absolutely outstanding excellent work and thank you for your efforts !! I too am so glad this week is over but when I saw on 29th October Dr Kunwar announces that it has allotted and issued 426,500 ordinary shares of 3 pence each ("New Ordinary Shares") credited as fully paid at a price of 35 pence per share in respect of the exercise of 426,500 options with an exercise price of 35 pence held by option holders, including 400,000 held by Dr Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer of the Company; 20,000 held by Vaseem Palejwala, Director of Clinical Operations of the Company and 3,500 held by Jules Jacob, Senior Director, CMC & Non-Clinical Development of the Company.
Application will be made for the 426,500 New Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on or around 4 November 2020. The New Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.
I felt that if they are prepared to risk that amount of holding then it has got to be a safe punt !! You know what they say ‘m Follow the Money ‘.It’s now just Beer o’clock so have a great weekend all !!
Whimax thanks for sharing. He did mention it one of my previous emails that he was aware. Like he said lets hope someone takes action.
Now that this demerger is over we need to focus on the more serious issues at hand. Like finding the treatment for covid...
http://finance.yahoo.com/news/regeneron-stop-enrolling-very-sick-151542504.html?
They are all falling like flies. Tils will soon be the last one standing... I hope
I wrote another lengthy email to Dr Kunwar after close of play today, outlining again what is going on regarding the Shorting and Algorithm Bot on the Nasdaq, and the long and short term damage this will do both to the share price and the development of Tiziana in general if this continues unchecked.
I received the following reply back.
“ I understand your concerns and frustration. Hoping that SEC notices it and take actions against the stock price manipulations.
You might want to write to them directly”
In response to his final sentence I responded that I had already submitted a SEC Complaint 2 months ago, which unsurprisingly, hadn’t done any good thus far.
The TILS BoD are clearly aware of what is going on. I’m hoping they are being proactive in trying to rectify the situation.
Have a good weekend all. I for one and glad this week is over.